Reproducibility over time of the urinary diclofenac/4′-OH diclofenac ratio among different CYP2C9 genotypes

European Journal of Drug Metabolism and Pharmacokinetics

Volumn 28, Issue 3, 2003, Pages 213-215

  Dorado, Pedro ^a   Berecz, Roland ^a   Cáceres, Macarena C ^a   Conzález, Idilio ^a   Llerena, Adrián ^a,b  

^a UNIVERSITY OF EXTREMADURA   (Spain)

^b UNIVERSITY OF BEIRA INTERIOR   (Portugal)

Author keywords

CYP2C9; Cytochrome P450; Diclofenac; Losartan

Indexed keywords

CYTOCHROME P450 2C9; DICLOFENAC;

ADULT; ALLELE; ARTICLE; DRUG HYDROXYLATION; DRUG URINE LEVEL; ENZYME ACTIVITY; FEMALE; GENETIC VARIABILITY; GENOTYPE; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; REPRODUCIBILITY;

EID: 0141831776     PISSN: 03787966     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03190487     Document Type: Article

References (9)

1. Xie H.G., Prasad H.C., Kim R.B., Stein C.M. (2002): CYP2C9 allelic variants: ethnic distribution and functional significance. Adv. Drug. Deliv. Rev., 54, 1257-1270.
2. Miners J.O., Birkett D.J. (1998): Cytochrome P4502C9: an enzyme of major importance in human drug metabolism. Br. J. Clin. Pharmacol., 45, 525-538.
3. Lee C. R., Goldstein J.A., Pieper J. (2002): Cytochrome P450 2C9 polymorphisms: a comprehensive review of the in vitro and human data. Pharmacogenetics, 12, 251-263.
4. Shimamoto J., Ieiri I., Urae A., et al. (2000): Lack of differences in diclofenac (a substrate for CYP2C9) pharmacokinetics in healthy volunteers with respect to the single CYP2C9*3 allele. Eur. J. Clin. Pharmacol., 56, 65-68.
5. Morin S., Loriot M.A., Poirier J.M., et al. (2001): Is diclofenac a valuable CYP2C9 probe in humans? Eur. J. Clin. Pharmacol., 56, 793-797.
6. Yasar Ü., Eliasson E., Forslund-Bergengren C., et al. (2001): The role of CYP2C9 genotype in the metabolism of diclofenac in vivo and in vitro. Eur. J. Clin. Pharmacol., 57, 729- Xie 735.
7. Dorado P., Berecz R., Cáceres M. C., LLerena A. (2003): Analysis of diclofenac and its metabolites by high-performance liquid chromatography: Relevance of CYP2C9genotypes in diclofenac urinary metabolic ratios. J. Chromatogr B., 789, 437-442.
8. Dorado P., Berecz R., Norberto M.J., Yasar Ü., Dahl M.-L., LLerena A. (2003): CYP2C9 genotypes and diclofenac metabolism in Spanish healthy volunteers. Eur. J. Clin. Pharmacol., (in press).
9. Yasar Ü., Forslund-Bergengren C., Tybring G., et al. (2002): Pharmacokinetics of losartan and its metabolite E-3174 in relation to the CYP2C9 genotype. Clin. Pharmacol. Ther., 71, 89-98.